CAESAREA, Israel – November 18, 2013 – Mazor Robotics Ltd. (TASE: MZOR; NASDAQCM: MZOR), the developer of Renaissance®, an innovative surgical guidance system and its complementary products, announced today its financial results for the third quarter and nine months ended September 30, 2013.
“We continue to see strong demand for our systems as we sold 16 Renaissance systems in the first nine months of 2013, representing a 33% increase compared to the year-ago nine month period,” commented Ori Hadomi, President and Chief Executive Officer. “We are confident that our active pipeline will allow us to continue penetrating more hospitals and hospital corporations, a strategy reinforced with a system sale recently announced in November. Our strengthened balance sheet resulting from the recent successful ADS offering provides the resources to expand our sales and marketing footprint which will facilitate increased adoption of Renaissance.”
THIRD QUARTER 2013 FINANCIAL RESULTS ON IFRS BASIS (“GAAP”)
Consistent with the Company’s previous announcement, revenue for the three months ended September 30, 2013 was $3.1 million compared to $4.1 million in the three months ended September 30, 2012. U.S. generated revenue decreased to $2.3 million from $3.3 million in the year-ago quarter, primarily due to the commercial sale of one Renaissance® systems and one system upgrade, compared with sales of four systems in the third quarter of 2012. International non-U.S. revenue was $0.8 million compared to $0.8 million reported in the third quarter of 2012, reflecting one system sale in the third quarter of 2013. Recurring revenue from system kit sales, services and other totaled $1.5 million in the third quarter of 2013, compared with $1.1 million, in the third quarter of 2012.
Gross margin for three months ended September 30, 2013 was 73.2% compared to 80% in the year-ago quarter, due to lower system sales in the third quarter of 2013.
Total operating expenses in the third quarter of 2013 were $5.8 million compared to $3.5 million in the third quarter of 2012, reflecting the Company’s investments in sales and marketing resources. Operating loss for the third quarter of 2013 was $3.5 million compared to an operating loss of $0.2 million in third quarter of 2012. Net loss for the third quarter of 2013 was $3.5 million, or $0.10 per share, compared to a net loss of $0.2 million, or $0.01 per share in the third quarter of 2012.
Cash used in operating activities in the third quarter of 2013 was $3.8 million, compared to $0.3 million provided by operating activities in the third quarter of 2012. As of September 30, 2013, cash, cash equivalents and marketable securities totaled $22.9 million. Subsequent to the end of the 2013 third quarter, the Company sold 2.76 million ADSs, with total net proceeds to the Company of $43.6 million, after deducting underwriters’ fee and discounts.
THIRD QUARTER 2013 FINANCIAL RESULTS ON NON-GAAP BASIS
The tables below include a reconciliation of the Company’s GAAP results to non-GAAP results. The reconciliation primarily relates to non-cash expense in the amount of $0.4 million with respect to share based compensation and intangible asset amortization in the third quarter of 2013. On a non-GAAP-basis, the net loss in the third quarter of 2013 was $3.1 million, or $0.09 per share, compared to breakeven in the third quarter of 2012.
NINE-MONTH ENDED SEPTEMBER 30, 2013 FINANCIAL RESULTS IFRS BASIS (“GAAP”)
For the nine months ended September 30, 2013, revenue totaled $14.3 million, representing a 51% increase compared to $9.4 million for the nine months ended September 30, 2012. The growth is attributed to the increased sales of the Company’s Renaissance system, both in the U.S. and globally. In the first nine months of 2013, the Company sold a total of 16 Renaissance systems and one system upgrade compared to 12 systems in the first nine months of 2012. Gross margin for the nine months ended September 30, 2013 was 78.6% compared with 77.2% in the nine months ended September 30, 2012. The Company’s net loss for the first nine months of 2013 was $18.5 million, or $0.61 per share compared to $2.6 million, $0.12 per share, in the first nine months of 2012.
NINE MONTHS ENDED SEPTEMBER 30, 2013 FINANCIAL RESULTS ON NON-GAAP BASIS
On a non-GAAP-basis, net loss for the first nine months of 2013 was $4.1 million, or $0.13 per share, compared to a net loss of $1.9 million, or $0.09 per share in the first nine months of 2012.
CONFERENCE CALL INFORMATION
The company will host a conference call to discuss these results on Monday, November 18, 2013, at 8:30 AM ET (3:30 PM IST). Investors within the United States interested in participating are invited to call 877-941-6009 and reference the Conference ID: 4650552. Participants in Israel can use the toll free dial-in number 1809-21-4368 and reference the same Conference ID number. All other international participants can use the dial-in number 480-629-9819, using the same Conference ID.
A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 800-406-7325 and reference the Replay Access Code: 4650552. All international callers can dial 303-590-3030, using the same Replay Access Code.
To access the webcast, please visit www.mazorrobotics.com, click ‘Investors.’
Use of Non-GAAP Measures
In addition to disclosing financial results calculated in accordance with generally accepted accounting principles in conformity with International Financial Reporting Standards (GAAP), this press release contains Non-GAAP financial measures for gross profit, operating expenses, operating loss, financing income, net income and basic and diluted earnings per share that exclude the effects of non-cash expense of amortization of intangible assets, stock-based compensation and revaluation of the fair value of the derivative instruments. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance that enhances management’s and investors’ ability to evaluate the company’s net income and earnings per share and to compare them to historical net income and earnings per share.
The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the business internally and therefore decided to make these non-GAAP adjustments available to investors.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQCM: MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance®, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants in the United States and Europe. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology.
For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal Securities laws. Forward-looking statements are statements that are not historical facts and may include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. For example, forward-looking statements are used in this press release, when we discuss our belief that our active pipeline will allow us to continue penetrating more hospitals and hospital corporations, or when we discuss expanding our sales and marketing footprint to accelerate adoption of Renaissance systems. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC), including those discussed under the heading “Risk Factors” in Mazor’s registration statement on Form F-1 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
